The Biohaven Investment Thesis and Valuation Paradigm
In assessing the equity profile of Biohaven, analysts and institutional investors must fundamentally alter the traditional frameworks used to evaluate mature, cash-flowing assets. Biohaven operates entirely within the clinical and pre-clinical stages of drug development, reporting zero commercial product revenue.
Precise real-time figures for dividend yield, Adjusted Funds From Operations (AFFO), Funds From Operations (FFO), and Price-to-FFO ratios are unavailable; the following estimates are based on alternative fundamental analyses appropriate for pre-revenue biotechnology entities. Biohaven does not pay a dividend, has no history of returning capital to shareholders via distributions, and operates with deeply negative operating cash flows. Consequently, the equity cannot be valued on yield or traditional coverage ratios.
Alternative Valuation and Market Consensus
Because FFO and Price-to-Earnings (P/E) multiples are mathematically invalid for an entity generating net losses of $129.3 million per quarter, valuation must be derived from pipeline probability-adjusted net present value (RNPV) models, sum-of-the-parts (SOTP) analyses, and comparative market capitalizations of similar clinical-stage peers.
The following data points outline the current market consensus and baseline trading parameters for Biohaven as of late Q4 2026:
Market Capitalization: Approximately $2.09 billion to $2.33 billion, fluctuating on a trailing 30-day basis. Share Price Volatility: Trading in mid-November 2026 near $13.82 to $15.52, against a 52-week high of $18.24 and a 52-week low of $7.48. Analyst Consensus Target: The mean 12-month price target across 16 Wall Street analysts sits between $19.25 and $20.80, representing an estimated 40% to 50% upside from current trading levels. The range of these targets is exceptionally wide, spanning from a bearish $10.00 to a highly optimistic $48.00. Institutional Ownership: Hedge funds and institutional investors hold approximately 88.78% of outstanding shares, indicating a market heavily dominated by sophisticated biotech-focused capital.
The massive variance in analyst price targets—from $10.00 to $48.00—perfectly encapsulates the binary nature of Biohaven's pipeline. The bullish thesis relies on the commercial validation of its protein degradation platforms and eventual FDA approval of its neurological assets, which could support a multi-billion-dollar commercial opportunity. The bearish thesis, conversely, focuses on the execution risks of late-stage trials, the persistent threat of regulatory holds, and the looming reality of shareholder dilution if clinical timelines are extended. To understand which trajectory is more probable, investors must look directly at the clinical data, beginning with the company's most promising catalyst: BHV-1300.
Clinical-Stage Peer Comparison
To ground Biohaven's valuation in the broader biotechnology landscape, it must be benchmarked against peers operating with similar capital structures, immunology/neurology focuses, and late-stage clinical pipelines. The table below compares Biohaven against Immunovant (IMVT) and Roivant Sciences (ROIV).
| Metric | Biohaven (BHVN) | Immunovant (IMVT) | Roivant Sciences (ROIV) | | :--- | :--- | :--- | :--- | | Market Capitalization | ~$2.09B - $2.33B | ~$6.31B - $7.08B | ~$26.03B - $30.23B | | Enterprise Value (EV) | ~$2.2B (Estimated) | ~$4.91B | ~$22.30B - $25.12B | | Available Cash / Liquidity | ~$600M (Pro-forma) | ~$797.8M | ~$3.9B - $4.2B | | Estimated Cash Runway | Deep into 2028 | ~26 months (Launch of IMVT-1402) | Runway into profitability | | Lead Asset & Stage | BHV-1300 (Phase 3) | IMVT-1402 (Phase 3) | brepocitinib (NDA/Phase 3) |
Precision Immunology: The Graves' Disease Catalyst
The core driver of recent bullish sentiment surrounding Biohaven is the rapid advancement of its proprietary MoDE (Microbody-directed Extracellular) protein degrader platform. Specifically, the lead candidate, BHV-1300, has emerged as a potential paradigm shift in the treatment of autoimmune disorders, beginning with Graves' disease.
The Biological Setup: An Unmet Need Spanning 70 Years
To grasp the commercial and clinical significance of BHV-1300, one must first understand the underlying pathology of Graves' disease. Graves' disease is an autoimmune condition that serves as the most common cause of hyperthyroidism (an overactive thyroid gland). The disease is driven by the body's aberrant production of autoantibodies—specifically TSHR-IgG1 (Thyroid Stimulating Hormone Receptor Immunoglobulin G1)—which mistakenly bind to and overstimulate the thyroid gland. This constant overstimulation results in systemic toxicity, causing severe anxiety, rapid heartbeat, tremors, and severe ocular complications known as thyroid eye disease.
Strikingly, the standard of care for Graves' disease has not seen a novel, FDA-approved therapeutic intervention in over 70 years. Current treatments are entirely blunt instruments: anti-thyroid medications (which broadly block hormone production but do not stop the autoimmune attack), radioactive iodine therapy (which destroys the thyroid gland entirely), or total surgical thyroidectomy. These interventions force the patient into a lifelong dependency on synthetic thyroid hormone replacements. None of these legacy treatments address the root cause of the disease: the pathogenic TSHR-IgG1 autoantibodies.
BHV-1300: Mechanism and Clinical Data
BHV-1300 is designed to fundamentally alter this treatment landscape. Exclusively licensed from Yale University, the MoDE platform utilizes small molecules designed to harness the body's natural hepatic (LIVER) clearance mechanisms. The drug binds specifically to the pathogenic IgG antibodies circulating in the bloodstream and escorts them to the liver, where they are selectively destroyed. Unlike traditional immunosuppressants, BHV-1300 is designed to leave the rest of the immune system intact.
The clinical validation for this approach was showcased at the 2026 American Thyroid Association (ATA) Annual Meeting, built upon highly compelling Phase 1b data:
Deep Autoantibody Reduction: Weekly subcutaneous administration of 1000 mg of BHV-1300 achieved mean reductions in pathogenic TSHR-IgG1 autoantibodies of greater than 80% by week 12 in patients suffering from Graves' hyperthyroidism. Rapid Hormone Normalization: Patients experienced a rapid normalization of free T4 (thyroxine) thyroid hormones at a median of just 3 weeks, and normalization of free T3 (triiodothyronine) at a median of 5 weeks. Selective Preservation: The therapy successfully targeted the disease-driving IgG1, IgG2, and IgG4 subclasses while sparing IgG3 and other crucial immune components (IgA, IgM, and IgE), maintaining the patient's baseline cellular immunity. Tolerability: The drug has demonstrated a favorable safety profile to date, with no clinically significant increases in cholesterol, decreases in albumin, or signs of liver toxicity. Furthermore, it utilizes a patient-friendly subcutaneous autoinjector, eliminating the need for burdensome intravenous infusions.
These figures represent a profound breakthrough in precision immunology. By targeting the pathogenic root cause of the disease while sparing healthy antibodies, BHV-1300 differentiates itself dramatically from competing systemic immunosuppressants, such as FcRn inhibitors (e.g., argenx's efgartigimod / VYVGART, UCB's rozanolixizumab / RYSTIGGO, and Johnson & Johnson's nipocalimab / IMAAVY), which broadly and indiscriminately lower all IgG levels [cite: 1, 2]. The rapid normalization of thyroid hormones within three to five weeks in patients who remained hyperthyroid despite standard antithyroid drug therapy is a highly compelling efficacy signal that has directly justified the compound's immediate transition into late-stage testing.
The Pivotal Phase 3 Trial (NCT07661056)
Capitalizing on this momentum, Biohaven initiated a pivotal Phase 3 trial for BHV-1300 in June 2026. The trial design reflects an aggressive push toward commercialization: it is a randomized, double-blind, placebo-controlled study targeting approximately 300 adults. The primary endpoint is the restoration of normal thyroid function at week 26 in the complete absence of legacy antithyroid drug therapy.
As of Q3 2026, the trial is actively enrolling across more than 55 sites in the United States and Canada, with further global expansion slated for Japan, the UK, Australia, and the EU into early 2027 (Biohaven Investor Relations). If the Phase 3 data successfully replicates the deep, 80% autoantibody suppression seen in Phase 1b, Biohaven will hold the keys to the first true disease-modifying therapy for Graves' disease in modern medical history—a condition that afflicts roughly 1% of the global population, predominantly women.
Strategic Monetization: The Ono Pharmaceutical and SK Biopharmaceuticals Deals
To fund the immense capital requirements of conducting concurrent global Phase 3 trials in immunology and neurology, Biohaven executed two massive licensing agreements in the third quarter of 2026. These deals are crucial to the equity thesis, as they dramatically alter the company's leverage profile and cash runway.
The Ono Pharmaceutical Asian License (MoDE Platform)
In October 2026, Biohaven entered an exclusive regional licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. (Ono Press Release) [cite: 3, 4], covering the MoDE pan IgG degrader portfolio (led by BHV-1300, alongside follow-on degraders BHV-1310 and BHV-1320).
The geographic parameters and financial terms of this agreement provide Biohaven with critical non-dilutive capital while carefully preserving its most lucrative market rights:
Geographic Scope: Ono gains exclusive rights to develop and commercialize the MoDE portfolio strictly in Japan, South Korea, Taiwan, and the Association of Southeast Asian Nations (ASEAN). Biohaven retains all rights to the U.S., European, and Chinese markets. Upfront Capital: Biohaven secured up to $100 million in near-term payments, anchored by a confirmed $80 million upfront cash payment received on October 20, 2026. Milestones and Royalties: An additional $20 million milestone payment is anticipated within one year of signing. Should the drugs reach commercialization in the covered territories, Biohaven is entitled to royalties of approximately 20% on net sales generated by Ono.
This transaction is a masterstroke of biotech capital structuring. By carving out specific Asian territories, Biohaven monetizes regions where it lacks direct commercial infrastructure, injecting $80 million of immediate, non-dilutive liquidity into its balance sheet. This maneuver validates the scientific premise of the MoDE platform in the eyes of a major global pharmaceutical player while keeping the hyper-lucrative U.S. and European markets wholly owned for future realization.
The SK Biopharmaceuticals Global License (Kv7 Platform)
The second, and vastly larger, transaction occurred in August 2026. Biohaven granted SK Biopharmaceuticals Co., Ltd. (SKBP) an exclusive, worldwide license to its Kv7 ion channel platform, primarily centered on the focal epilepsy asset opakalim (BHV-7000) (SK Biopharmaceuticals Press Release) [cite: 5, 6].
The financial scope of the SKBP deal completely reshapes Biohaven's near-term balance sheet:
Cash Consideration: The agreement provides Biohaven with $400 million in total near-term cash, structured as $350 million payable at closing and an additional $50 million payable one year post-closing. Future Milestones and Royalties: Biohaven remains eligible for up to $150 million in development and regulatory milestones. Furthermore, Biohaven retains tiered royalties ranging from the mid-teens to low twenties percent on U.S. net sales, and mid-single-digit royalties on ex-U.S. sales. Cost Assumption: Crucially, SKBP assumes all future funding responsibilities for the Kv7 program's clinical costs. SKBP also absorbs certain legacy milestone and royalty obligations owed to Knopp Biosciences (the original developer of the asset), totaling up to $245 million.
The conclusion of the Hart-Scott-Rodino (HSR) antitrust waiting period expired on October 28, 2026, paving the way for the deal's final closure. The strategic rationale here is clear: Biohaven has chosen to heavily de-risk its neurological pipeline. By offloading the operational and financial burden of the costly epilepsy trials to SKBP—a company with an established U.S. epilepsy commercial infrastructure built around its Xcopri franchise—Biohaven captures $350 million in immediate cash to redirect toward its wholly-owned precision immunology assets like BHV-1300 and BHV-1400.
Neurological Pipeline Risks: The Opakalim FDA Clinical Hold
While the SK Biopharmaceuticals deal appears wildly lucrative on paper, it is deeply intertwined with Biohaven's most severe immediate red flag: a regulatory intervention by the FDA.
The Kv7 Mechanism and Epilepsy
Opakalim (BHV-7000) is designed as a highly selective activator of Kv7.2/7.3 potassium channels. In patients with refractory focal epilepsy, the neurons in the brain are excessively excitable, leading to seizures. Opakalim works by opening these potassium channels, which essentially calms the neurons and reduces excitability. This mechanism of action is distinctly different from traditional GABA-receptor modulating anti-seizure drugs, theoretically offering robust efficacy without the debilitating sedative side effects associated with legacy epilepsy medications.
The FDA Partial Clinical Hold
On September 4, 2026—just days after Biohaven signed the $400 million term sheet with SK Biopharmaceuticals—the FDA issued a partial clinical hold on the entire opakalim program.
The specifics of this regulatory action represent a highly complex risk matrix for equity holders:
The Cause: The FDA paused the program due to "insufficient information" regarding a specific metabolite discovered during routine pre-clinical non-human rodent testing. A metabolite is a biochemical byproduct created when the body breaks down a drug. The FDA requires additional non-clinical (animal) studies to explicitly characterize whether this rodent-specific metabolite poses any safety risk to human subjects. The Clinical Impact: The partial hold restricts the enrollment of new patients into the opakalim trials. However, the FDA explicitly allowed the continued dosing of the more than 600 human patients who were already randomized and participating in the program. Timeline Preservation: Because the Phase 3 RISE-3 trial (NCT06309966) was already fully enrolled and randomized prior to the September 4th hold, the immediate timeline for top-line data readout remains entirely intact and on track for the second half of 2026. The companion Phase 3 RISE-2 study, however, is heavily impacted as it can no longer recruit new subjects pending the resolution of the hold.
The optics of receiving an FDA clinical hold mere days after announcing a massive global out-licensing deal initially shocked the market, causing a sharp 15% intraday drop in BHVN's stock price (Fierce Biotech). However, aggressive panic may be unwarranted based on the underlying facts. Biohaven management has confirmed via SEC filings that SK Biopharmaceuticals was provided full, un-redacted access to all clinical and non-clinical data—including the exact rodent metabolite findings in question—prior to the execution of the licensing agreement. SKBP proceeded with the $350 million upfront commitment fully aware of the regulatory risk, implying a high degree of confidence from a specialized neurology player that the metabolite issue is species-specific (confined to rodents) and will not derail human commercialization.
Nonetheless, a clinical hold is the most significant red flag a development-stage biopharma can face. Until Biohaven submits the requested non-clinical data and the FDA formally lifts the hold to allow new enrollment in RISE-2, the Kv7 program operates under a dark cloud of regulatory uncertainty. Under statutory guidelines (21 CFR § 312.42(e)), once Biohaven submits a complete response addressing all deficiencies, the FDA operates on a strict 30-calendar-day review clock to evaluate the data. However, the trial remains completely paused until the FDA provides explicit, formal notification that the hold is lifted (FDA.gov Regulatory Information) [cite: 7, 8].
Additional Pipeline Assets: Troriluzole and BHV-1400
Beyond Graves' disease and epilepsy, Biohaven's valuation is buoyed by two other critical late-stage assets that provide necessary diversification.
Troriluzole (Spinocerebellar Ataxia)
Spinocerebellar ataxia (SCA) is a rare, progressive, and fatal neurodegenerative disease with no currently approved treatments. Biohaven's asset, Vyglxia (troriluzole), has had a highly tumultuous regulatory history, suffering prior data misses and regulatory pushback. However, in Q3 2026, the FDA formally accepted Biohaven's resubmitted New Drug Application (NDA) as a complete response to a previous action letter.
The FDA has assigned a user fee goal date (PDUFA date) in the first quarter of 2027 and plans to convene an Advisory Committee (AdComm) meeting to discuss the drug's efficacy and safety data. The acceptance of this NDA represents a massive near-term catalyst. If the AdComm votes favorably and the FDA grants approval in early 2027, Biohaven will transition overnight from a clinical-stage entity to a commercial rare-disease company. The total addressable market for SCA is estimated at over $1.2 billion, providing a lucrative foundation for independent commercial revenue. However, investors must price in substantial approval risk, given the drug's historically uneven clinical readouts.
BHV-1400 (IgA Nephropathy)
Parallel to the MoDE platform, Biohaven is advancing its TRAP (Targeted Receptor Autoantibody Pathway) platform. The lead TRAP candidate is BHV-1400, an extracellular degrader specifically targeting galactose-deficient IgA1 (Gd-IgA1), the pathogenic driver of IgA nephropathy (IGAN), a severe kidney disease.
Early Phase 1b data has been exceptional, showing a rapid, greater than 60% mean reduction in pathogenic Gd-IgA1 within hours of administration, significantly outperforming competing biological mechanisms like BAFF/APRIL inhibitors. Furthermore, preliminary observations showed tangible improvements in kidney function (increased eGFR (estimated glomerular filtration rate), decreased spot UPCR (urine protein-creatinine ratio), and decreased hematuria) within one month of dosing. Biohaven remains on track to initiate a massive, global pivotal Phase 3 trial for BHV-1400 in the fourth quarter of 2026, expanding the company's precision immunology footprint deep into nephrology.
Financial Health, Leverage, and Capital Structuring
Evaluating Biohaven's financial health requires an analysis of its operating cash burn relative to its available liquidity, leverage, and ongoing equity dilution.
Income Statement and Cash Burn
According to the company's Q3 2026 Form 10-Q filed with the SEC on October 29, 2026, Biohaven is operating at a severe, albeit narrowing, deficit:
Net Loss: The company reported a net loss of $129.3 million, or $0.86 per share, for the three months ended September 30, 2026. This represents a significant improvement over the $173.4 million net loss ($1.64 per share) reported in Q3 2025. Operating Expenses: Total operating expenses contracted to $126.4 million for Q3 2026. Research and development (R&D) expenses accounted for $101.9 million of this total (down from $141.2 million in 2025). This $39.3 million year-over-year reduction in R&D spend was directly attributed to a strategic reprioritization of pipeline assets implemented in late 2025, demonstrating management's willingness to aggressively cut non-core clinical expenditures to preserve capital. General and administrative (G&A) expenses also fell to $24.6 million. Nine-Month Run Rate: For the first nine months of 2026, net cash used in operating activities stood at $341.9 million. This equates to an average quarterly operating burn rate of approximately $114 million.
Biohaven operates with a staggering accumulated deficit of $2.48 billion since inception, underscoring the massive capital requirements of shepherding novel molecules through Phase 3 trials.
Balance Sheet, Leverage, and Cash Runway
As of September 30, 2026, Biohaven's balance sheet presented an alarming picture of impending liquidity exhaustion, which must be contextualized by subsequent post-quarter events.
Stated Q3 Liquidity: At the end of Q3 2026, cash and cash equivalents dropped to $95.8 million, with an additional $65.4 million in marketable securities, providing total visible liquidity of approximately $164.0 million. Leverage (Notes Payable) & Debt Metrics: The company carries a highly restrictive debt burden. Notes payable increased to $264.3 million (up from $238.9 million at the end of 2025, largely due to a $22.5 million fair value adjustment). This debt carries severe covenants; for instance, if Biohaven's audited financial statements for 2026 carry a "going concern" qualification, it could trigger an event of default, allowing debt holders to accelerate payment of outstanding amounts. The specifics of the $264.3 million in notes payable are governed by an April 2025 Note Purchase Agreement. Crucially, this debt does not carry a standard fixed cash interest rate that drains operational liquidity. Instead, the cost of debt is structured as a return generated through a revenue payment percentage (ranging from 6.25% to 10% on future net sales of assets like troriluzole), alongside a 35% milestone payment upon the first FDA or EMA marketing approval. Total repayment is capped via a multiplier of 120% to 225% of the funded amount. The specific maturity date of this debt is heavily tied to regulatory success: the notes mature on the eighth anniversary of the effective date (April 28, 2033) if no marketing approval is achieved by December 31, 2030, or the tenth anniversary (April 28, 2035) if approval is secured (SEC.gov Form 8-K) [cite: 9]. Shareholders' Deficit: The relentless cash burn and growing debt obligations pushed Biohaven into negative equity territory. Total shareholders' deficit stood at $98.2 million as of September 30, 2026, a stark reversal from the positive $52.1 million equity position held at the end of 2025. Equity Dilution: To survive the first three quarters of 2026, Biohaven raised $178.9 million through aggressive common share issuances. Consequently, shares outstanding swelled to 151,055,160 as of September 30, 2026, up nearly 14% from 132,775,113 at the end of 2025. This dilution permanently reduces existing shareholders' percentage ownership.
Viewed strictly through the lens of the September 30th snapshot, Biohaven possessed roughly 1.4 quarters of cash runway—enough to survive only until February 2027. However, this analysis is fundamentally incomplete without factoring in the October monetization events.
The strategic brilliance of the Ono and SK Biopharmaceuticals deals now becomes apparent. On October 20, 2026, Biohaven received the $80 million upfront payment from Ono. Upon the imminent closing of the SKBP agreement, Biohaven will receive a monumental $350 million upfront cash injection. The combined $430 million in immediate, non-dilutive liquidity effectively eradicates the near-term "going concern" risk. Factoring in the $164 million Q3 cash balance and the $430 million in new licensing revenue, Biohaven's pro-forma liquidity balloons to nearly $600 million. At a quarterly burn rate of $114 million, this extends the company's cash runway deep into 2028, bridging the gap to crucial commercialization events and late-stage pipeline readouts without the immediate need for further value-crushing equity dilution.
Risks, Red Flags, and Open Questions
Despite the transformative licensing deals and groundbreaking precision immunology data, an investment in Biohaven carries profound, asymmetric risks inherent to clinical-stage biotechnology.
1. The FDA Partial Clinical Hold Resolution: The most glaring red flag remains the regulatory status of opakalim (BHV-7000). While SK Biopharmaceuticals assumed the financial risk, Biohaven's pipeline valuation remains tethered to the drug's success. If the FDA determines that the rodent-specific metabolite poses a legitimate danger to human subjects—or if the requested non-clinical animal data proves inconclusive—the FDA could upgrade the partial hold to a full clinical hold, effectively killing the asset. The market will remain highly sensitive to any updates regarding the FDA's posture on this program through the end of 2026, as the FDA utilizes a strict 30-day clock to respond to data submissions without guaranteeing an immediate resumption of the trial. 2. The Troriluzole Advisory Committee (AdComm) Risk: While the FDA accepted the NDA resubmission for troriluzole in SCA, the upcoming Q1 2027 AdComm meeting introduces immense binary risk. Biohaven has historically struggled to present airtight efficacy data for its ataxia programs, often relying on post-hoc analyses to justify statistical significance. If the independent AdComm panel votes against recommending approval based on weak efficacy or safety signals, the FDA will almost certainly issue a Complete Response Letter (CRL), erasing over a billion dollars in projected commercial value and delaying potential revenue-sharing debt payoffs. 3. Execution Risk in Phase 3 Immunology Trials: The bullish thesis for BHVN rests entirely on the assumption that the spectacular >80% autoantibody degradation observed in the Phase 1b trial of BHV-1300 will replicate in the 300-patient Phase 2/3 pivotal trial. Clinical history is littered with promising Phase 1 therapeutics that failed to demonstrate statistically significant clinical endpoints in massive, double-blind Phase 3 environments. If BHV-1300 fails to restore normal thyroid function at week 26 without legacy antithyroid support, the entire foundational premise of the MoDE platform will collapse. 4. Covenant Risks on Notes Payable: Even with the incoming licensing cash, the $264.3 million in notes payable restricts Biohaven's operational flexibility. The debt covenants strictly govern the company's ability to dispose of assets, make investments, undergo acquisitions, or pay dividends. Any severe clinical setback that threatens the company's ability to maintain a clean audit without a "going concern" warning could theoretically trigger a catastrophic default acceleration.
Conclusion
Biohaven represents the quintessential high-risk, high-reward biotechnology equity. For institutional investors, the narrative has firmly pivoted away from the legacy neurology portfolio and toward the revolutionary potential of the MoDE and TRAP extracellular protein degradation platforms. The Phase 1b data for BHV-1300 in Graves' disease is nothing short of extraordinary, offering the first mechanistic cure for a systemic autoimmune disease that has lacked innovation for seven decades.
The management team has executed a masterclass in non-dilutive capital structuring in Q3 2026. By out-licensing regional rights in Asia to Ono Pharmaceutical and offloading the expensive, regulatory-constrained Kv7 epilepsy program to SK Biopharmaceuticals, Biohaven has secured nearly half a billion dollars in upfront liquidity. This maneuvering shields existing shareholders from immediate, desperate equity dilution and provides the necessary capital to independently march its premier immunology assets through global Phase 3 trials.
However, investors must remain relentlessly focused on the open regulatory questions. The impending AdComm for troriluzole in Q1 2027 and the unresolved FDA partial clinical hold on opakalim will introduce massive volatility over the next six months. For those willing to underwrite the clinical execution risk, Biohaven offers one of the most compelling, well-funded precision immunology pipelines in the mid-cap biotechnology sector.
Sources: 1. drugpatentwatch.com 2. pharmaphorum.com 3. biohaven.com 4. prnewswire.com 5. biohaven.com 6. skbp.com 7. fda.gov 8. fda.gov 9. Link